(NASDAQ: BCTX) Briacell Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 5.13%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 15.2%.
Briacell Therapeutics's earnings in 2025 is -$19,621,152.On average, 1 Wall Street analyst forecast BCTX's earnings for 2026 to be -$7,758,623, with the lowest BCTX earnings forecast at -$7,758,623, and the highest BCTX earnings forecast at -$7,758,623. On average, 1 Wall Street analyst forecast BCTX's earnings for 2027 to be -$2,303,871, with the lowest BCTX earnings forecast at -$2,303,871, and the highest BCTX earnings forecast at -$2,303,871.
In 2028, BCTX is forecast to generate -$1,057,070 in earnings, with the lowest earnings forecast at -$1,057,070 and the highest earnings forecast at -$1,057,070.